Stockscreener 앱 받기
68.78
0.30%
-0.21
시간 외 거래:
69.20
0.42
+0.61%
Bridgebio Pharma Inc 주식(BBIO)의 최신 뉴스
BridgeBio to present encaleret data at endocrinology congress By Investing.com - Investing.com South Africa
BridgeBio Pharma to Present Phase 3 Infigratinib Achondroplasia Trial Results at ECE 2026, Focusing on Annualized Growth Velocity in Children Aged 3-11 - geneonline.com
MSN Money - MSN
BridgeBio to unveil Phase 3 rare-disease trial results in Prague - Stock Titan
BridgeBio seesaws after settlement in Pfizer Vyndamax patent dispute (update) - MSN
BridgeBio to Present Primary Results From the Phase 3 CALIBRATE Trial at 2026 ECE - Moomoo
BBIO SEC FilingsBridgebio Pharma 10-K, 10-Q, 8-K Forms - Stock Titan
[Form 4] BridgeBio Pharma, Inc. Insider Trading Activity - Stock Titan
Achondroplasia Pipeline Expands as 15+ Pharma Companies - openPR.com
BridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026 - The Manila Times
New heart failure data on BridgeBio drug lands late-breaking ESC slot - Stock Titan
William Blair Initiates BridgeBio Pharma(BBIO.US) With Buy Rating - Moomoo
BridgeBio Pharma Inc. (BBIO): Billionaire Tom Steyer Admires Upside Potential of This Stock - Insider Monkey
BridgeBio gains amid report of settlement in Pfizer Vyndamax patent dispute - MSN
Vanguard Group Inc. Increases Stake in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio (BBIO) Q2 2025 Earnings Transcript - AOL.com
(BBIO) Volatility Zones as Tactical Triggers - Stock Traders Daily
BBOT SEC FilingsBridgeBio Oncology Therapeutics, Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Truist Financial Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Raises Target Price to $102 - Moomoo
Truist Financial Keeps Their Buy Rating on BridgeBio Pharma (BBIO) - The Globe and Mail
BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ET - The Manila Times
After the bell: BridgeBio schedules Q1 results and program update - Stock Titan
Is Attruby’s Accelerating Launch and Star-Studded Awareness Campaign Altering The Investment Case For BridgeBio Pharma (BBIO)? - Yahoo Finance
The Escalator: BridgeBio Oncology Therapeutics, Haleon, AstraZeneca and more - Medical Marketing and Media
BridgeBio: Attruby's Early Dominance Makes The Bull Case Hard To Ignore (NASDAQ:BBIO) - Seeking Alpha
BridgeBio rises after late-stage trial win for dwarfism therapy - MSN
BridgeBio Pharma Is Maintained at Buy by Truist Securities - Moomoo
BridgeBio earnings on deck: Can Attruby sustain rapid growth? By Investing.com - Investing.com South Africa
BridgeBio earnings on deck: Can Attruby sustain rapid growth? - Investing.com
Analysts Are Bullish on Top Healthcare Stocks: BridgeBio Pharma (BBIO), Wave Life Sciences (WVE) - The Globe and Mail
BBIO Maintained by Truist Securities -- Price Target Raised to $102 - GuruFocus
Truist Financial Issues Positive Forecast for BridgeBio Pharma (NASDAQ:BBIO) Stock Price - MarketBeat
BBIO Reiterated by HC Wainwright & Co. -- Price Target Maintained at $100 - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
H.C. Wainwright reiterates BridgeBio Pharma stock rating on stable Vyndamax outlook - Investing.com Canada
BridgeBio Pharma, Inc. $BBIO Holdings Lifted by Moody Aldrich Partners LLC - MarketBeat
HC Wainwright Predicts Weaker Earnings for BridgeBio Pharma - MarketBeat
Pictet Asset Management Holding SA Has $96.96 Million Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Teachers Retirement System of The State of Kentucky Buys 17,343 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio launches ATTR-CM awareness campaign with Morgan Freeman By Investing.com - Investing.com South Africa
BridgeBio launches ATTR-CM awareness campaign with Morgan Freeman - Investing.com UK
BofA raises BridgeBio Pharma stock price target on Pfizer settlement clarity - Investing.com Canada
BridgeBio Oncology (Nasdaq: BBOT) details 2026 virtual meeting, board elections and auditor - Stock Titan
Raymond James reiterates BridgeBio stock rating on Vyndamax settlement By Investing.com - Investing.com Canada
Mizuho Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $106 - Moomoo
BBIO Reiterated by Mizuho -- Price Target Maintained at $106 - GuruFocus
Barclays sees Pfizer IP case progress as positive for BridgeBio stock - Investing.com Canada
Pfizer deals extend patent life for a top-selling rare disease drug - BioPharma Dive
0.14%
0.48%
자본화:
|
볼륨(24시간):